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Background: Telomere length dysregulation plays a major role in cancer develop-
ment and aging. Telomeres are maintained by a group of specialized genes known as 
shelterin and shelterin-associated proteins. In breast cancer lines it has been shown 
that shelterin proteins are dysregulated thereby affecting the telomere stability and 
contributing to the neoplastic conversion of the mammary epithelial cells. Interes-
tingly, the regulation of some of the shelterin genes is thought to be controlled epi-
genetically. Methods and Results: In this study, we set out to measure the effect of 
increased shelterin gene expression on telomere length in breast cancer cell line 
21NT treated with 5-aza-2-deoxycytidine (5-aza-CdR) using known telomere length 
assays. We measured telomere lengths using: Telomere Restriction Fragment length 
(TRF), absolute quantitative-PCR and cytogenetic Interphase Quantitative Fluores-
cent in situ Hybridization (iQ-FISH). We found that non-cytotoxic levels of 
5-aza-CdR affect telomere lengths by causing a significant and stable increase in te-
lomere lengths of the breast cancer cell line. The increase in telomere lengths was 
consistently observed when various telomere length methods were used. Conclu-
sions: Further investigation is required to understand the underlying mechanism in-
volved, and the significance of telomere length elongation in relation to clinical out-
come when epigenetic modifying drugs are utilized. 
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1. Introduction 
The importance of telomere structural integrity in cancer is becoming more evident [1]. 
Telomeres are implicated in cellular aging in vitro [2] and are thought to be a biomark-
er for aging in vivo [3]. Telomere shortening occurs as a result of each cellular division 
that can trigger cellular senescence leading to irreversible cell cycle arrest [4]. Telomere 
dysfunction can be governed by telomere length shortening or perturbation of the pro-
tective shelterin proteins, triggering DNA-damage response, resulting in formation of 
chromosome end-to-end fusions and genomic instability [5]. Induction of genomic in-
stability as a result of telomere dysfunction is thought to be critical in initiation of clon-
al evolution in cancer [4] [6]. Cancer cells maintain critically short telomere lengths by 
activating the two mechanisms of telomere length maintenance: 1) a telomere-specific 
DNA polymerase called telomerase (the primary mechanism), and 2) the secondary 
Alternative Lengthening of Telomeres mechanism known as ALT (a rare mechanism 
found in 10% - 15% of human tumors as well as immortalized cell lines [7]). The re-
verse transcriptase enzyme telomerase is responsible for the addition of hexanucleotide 
repeats TTAGGG, onto the 3’-end of a telomere, and consequently counters the process 
of replication-associated telomere shortening. In view of the fact that the capacity for 
limitless replication is a sign of cancer, telomerase or ALT must be activated to over-
come the process of telomere erosion and to enable replicative immortality [6]. Con-
trary to normal diploid somatic cells, 85% - 90% of tumor cells express high levels of 
telomerase which is responsible for maintaining the 2 - 4 kb telomere length of most 
cancer epithelial cells (carcinomas) [8]. 
The role of telomerase activation in human cancer development has been widely stu-
died [9] and it is important to understand how telomerase activation occurs in breast 
cancer. It has been reported that the up-regulation of telomerase is associated with cell 
immortalization and malignancy [10]. There is a strong body of evidence suggesting 
that short telomeres in breast cancer cells precipitate telomere dysfunction and this 
may be in part related to shelterin proteins and their expression levels in breast cancer 
cells [11]. Our previous study revealed that in a large panel of breast cancer cell lines 
the expression of the shelterin proteins was down-regulated due to the promoter me-
thylation [12]. Similarly, when breast cancer cell lines were treated with 5-aza-CdR 
alone or in combination with trichostatin A (TSA), the levels of POT1, TIN2 and TPP1 
shelterin proteins recovered to normal status [12]. Interestingly, we also reported the 
first observation of small but significant elongation of telomere lengths (1 - 2 kb in-
creases) in the breast cancer cell lines when treated with the epigenetic modifying drugs 
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5-aza-CdR and TSA that is also observed in clinical samples of sporadic and familial 
breast cancer patients [13]. Here, we set out to further investigate the effect of 5-aza- 
CdR and TSA on telomere lengths in breast cancer cell line, 21NT, by measuring the 
telomere lengths using various telomere lengths techniques. Our data shows consistent 
increase in telomere lengths of 21NT cells when treated with both epigenetic modifying 
drugs. Consequently, we think this increase in telomere length in breast cancer cells 
may have important clinical consequence when epigenetic modifying chemotherapies is 
used and therefore requires further investigation in identifying the underlying mechan-
ism. 
2. Materials and Methods 
2.1. Cell Culture Conditions, Maintenance and Treatment 
Breast cancer cell line, 21NT [14], normal mammary human epithelial cells (HMEC) 
(Lonza) and Murine lymphoma cells lines LY-R and LY-S [15] were grown in Modified 
eagle’s alpha (MEM) containing 10% foetal calf serum (Invitrogen), mammary epitheli-
al growth medium (MEGM basal medium and the single shot kit supplements and 
growth factors, Lonza) and in RPMI/1640 containing 10% foetal calf serum respectively 
as described previously [12]. The 21NT cells (1 × 105) were treated with 5-aza-CdR (5 
µM, Sigma, St. Louis, MO) and TSA (50 ng/ml, Sigma) for 24 hours initially, the me-
dium was changed and samples were taken at 72 hours (which included the first 24 
hours), 3 weeks, 6 weeks and 2 months. This treatment was based on the findings re-
ported previously [12]. The control cells were treated with 0.02% DMSO. 
2.2. Telomere length Measurement by Interphase Quantitative  
Fluorescent In Situ Hybridization (iQ-FISH) 
Samples were produced according to standard cytogenetic methods, with exception of 
Colcemid treatment. Briefly, cells were treated with 10ml of hypotonic buffer (0.075 M 
KCl) for 30 minutes at 37˚C, and were subsequently fixed with methanol and glacial 
acidic acid (3:1) solution. Cell suspensions were dropped onto slides and aged overnight 
at 55˚C. The telo-FISH method was applied as previously described [16]. 
Images of interphase nuclei were acquired on a digital fluorescence microscope 
(Zeiss Axioskop 2) equipped with a CCD camera (Photometrics) and Smart Capture 
software (Digital Scientific, Cambridge, UK) using fixed time exposure of 0.5 seconds 
and magnification of 63×. IP lab software (Digital Scientific) was used to analyze telo-
mere fluorescence intensity per cell. The signals from the average unmodified telomere 
fluorescence intensity (uTFI) were calculated as the total intensity of the telomeric sig-
nal utilizing the area under curve minus the background signal. The term unmodified 
fluorescence refers to the fact that no internal control was used to adjust for variability 
in fluorescence microscope. The experiment was repeated at least twice and each time 
100 cells were quantified for each sample. 100× magnification was used for capturing 
DMSO control cells whereas x63 magnification was used to capture the 5-aza-CdR 
treated and HMEC control. 
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2.3. Telomere Length Measurement by Telomere Restriction Fragment 
Length (TRF) 
Genomic DNA was extracted using the WizardTM Genomic DNA isolation Kit (Pro-
mega) according to the manufacturer’s protocol. TRF length measurement was per-
formed using the telomere length assay (Roche Diagnosis) and as previously described 
[17]. Approximately 3 µg of DNA was digested for 2 hours at 37˚C using a mixture of 
restriction enzymes Hinf I and Rsa I (20 Units for each) and was proceed with electro-
phoresis on an 8% agarose gel followed by Southern blotting and hybridization accord-
ing to the manufacturer guideline. The average TRF value was calculated by evaluating 
the telomeric signal (smear) relative to molecular weight standard as described in the 
Telomere Length Assay kit (Roche Diagnostics, Risch-Rotkreuz, Switzerland). The 
standard curve generated from the molecular weight is shown in Figure 1 and Figure 
2. The exposed X-ray film was scanned with (Desk Scanner G2710, HP) and analyzed 
using densitometry software ImageQuant 5.2 (Amersham Biosciences, USA). The mean 
telomere length was calculated as described in detail elsewhere [18] [19] and the OD  
 
 
Figure 1. A typical example of a TRF blot. Genomic samples were digested using restriction 
enzymes and hybridized with specific telomeric probes (see material and methods for details). 
The overall intensities of hybridization smears (separated by red dotted lines) were quantified 
as described in methods section. The control samples from the primary HMECs (p5 and p20) as 
well as the internal control of known telomere lengths is shown on the right. Samples loaded 
from left to right were as follows: 1) 21NT-untreated, 2) DMSO 72 hrs, 3) 5-aza-CdR 72 hrs, 4) 
5-aza-CdR/TSA 72 hrs, 5) 5-aza-CdR 3 weeks, 6) 5-aza-CdR/TSA 3 weeks, 7) 5-aza-CdR 6 
weeks, 8) 5-aza-CdR/TSA 6 weeks, 9) DMSO, 10) 5-aza-CdR 2 months, 11) 5-aza-CdR/TSA 2 
months, 12) HMEC1 p5, 13) HMEC1 P20, Lane 14) positive control with known telomere 
length. 




Figure 2. Example of the enzymatic digestion of gDNA showing smears of DNA after eletro-
phoresis. 3 µg of DNA was digested using Hinf I and Rsa I. Samples loaded from left to right 
were as follows: 1) 21NT-untreated, 2) DMSO 72 hrs, 3) 5-aza-CdR 72 hrs, 4) 5-aza-CdR/TSA 
72 hrs, 5) 5-aza-CdR 3 weeks, 6) 5-aza-CdR/TSA 3 weeks, 7) 5-aza-CdR 6 weeks, 8) 
5-aza-CdR/TSA 6 weeks, 9) DMSO, 10) 5-aza-CdR 2 months, 11) 5-aza-CdR/TSA 2 months, 
12) HMEC1 p5, 13) HMEC1 P20, Lane 14) positive control with known telomere length. 
 
values from the ImageQuant was used in the following formula to calculate the average  
telomere length from each sample: ( ) ( )TRF ODi ODi Li= ∑ ∑ , where ODi is the 
chemiluminescent signal and ODi/Li is the length of the TRF at position i. We drew a 
rectangular box containing 30 grids covering the whole telomere fragment smears. The 
average pixel from 30 grids were calculated and used in the above formula. 
3. Results and Discussion 
Previously [12], we reported that the addition of 5-aza-CdR (an epigenetic chemothe-
rapy drug) alone or in combination with TSA to the 21NT breast cancer cells affects 
shelterin expression. In order to clarify the exact effect of shelterin up-regulation in the 
breast cancer cell line on telomere length, we set out to measure telomere lengths using 
three commonly used techniques. TRF is a commonly used telomere length assay that is 
based on Southern hybridization [18]. It provides the most accurate measure of telo-
mere changes observed in cells in vitro. Alongside TRF we used a cytogenetic method 
based on the Q-FISH technique [20] [21] known as iQ-FISH [22]. Understanding the 
mechanism of telomere length stabilization and hence elongation in cancer will have 
profound implication in the clinical treatment choices. For example, the 5-aza-CdR is 
currently used clinically, at cytotoxic concentrations to inhibit cancer growth [23]. Re-
sistance to 5-aza-CdR develops rapidly and leads to relapse [24]-[26]; however, the ac-
tual mechanisms leading to resistance are poorly understood [27]. We therefore, have 
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hypothesized that this resistance may be due to the rapid telomere elongation. If treat-
ment of cancer with agents like 5-aza-CdR can lead to increases in telomere length, this 
in theory may disrupt the genomic stability leading to invasive growth potential and 
formation of an aggressive cancer phenotype. Therefore, it was imperative to investi-
gate our earlier observation of telomere length elongation in the breast cancer cell lines 
treated with epigenetic chemotherapy drugs to verify our previous findings. 
The treatment of 21NT cell line with 5-aza-CdR and 5-aza-CdR/TSA causes an in-
crease in average telomere length in the 21NT cells as shown in Figures 3(a)-(b). Pri-
mary HMEC (p5) was used as the normal control for telomere length measurements 






(b)                                    (c) 
Figure 3. Telomere length measurement by TRF and iQ-FISH. (a) The mean unmodified Telo-
mere Fluorescence Intensity (uTFI) was measured from untreated 21NT cells and primary 
HMECs (control) and from various time-points of treated 21NT with 5-aza-CdR and 5-aza- 
CdR/TSA. The experiment was repeated at least twice with a total number of 100 nuclei quanti-
fied for each sample. Error bars represent SEM. (b) Average telomere length measured using Te-
lomere Restriction Fragment (TRF) from the same sample type and time-points as described 
above. The experiment was performed twice from independent genomic DNA. Error bars 
represent standard deviation. (c) Scatter plot of telomere lengths measured by the three methods. 
Each individual average telomere length from treated cells (5-aza-CdR and 5-aza-CdR/TSA) was 
measured using the three methods previously described. The solid black line represents the me-
dian. On average, there is a small but significant increase in the telomere lengths of 21NT cells 
treated with 5-aza-CdR (p = 0.0033) and 5-aza-CdR/TSA (p = 0.0070). 
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Telomere elongation in treated 21NT (as compared to untreated controls) peaked at 
72 hours when measured with TRF and i-QFISH and continued for three weeks 
(Figures 3(a)-(b)). This increase in telomere length persisted in the cell populations for 
two months after treatment, and was detected by the two methods described in this pa-
per and by qPCR as described in [12]. Table 1 summarizes the overall telomere length  
elongation in the treated 21NT cells. Over a two-month period an average increase in 
telomere lengths of 1.06 kb (TRF) (p = 0.0718), 1.67 kb (qPCR) (p = 0.0570) and 1.83 
uTFI (i-QFISH) (p = 0.0232) was observed in the 21NT cells treated with 5-aza-CdR 
when compared to the untreated control groups. This increase in telomere length was 
visually noticeable when using the fluorescence microscope (Figure 4). 
The TRF method produce results in measurable and comparable units of kb. As it 
was not possible to convert telomere fluorescence intensity to kb, without having a 
standard curve from samples of known telomere length, we resorted in using an arbi-
trary unit of measurements called uTFI. It is interesting to note that the uTFI numerical 
values were in the same range as the TRF methods, which allowed us to plot the whisk-
er chart as evident in Figure 3(c) and Figure 5(a). This clearly shows that the treat-
ment with 5-aza-CdR and 5-aza-CdR/TSA induces an increase in telomere lengths for 
individual samples analyzed, with significant overall increases in the two treated groups 
(p = 0.0070 and p = 0.0033) (Figure 5). 
A significant drawback of the TRF method versus the q-PCR analysis is the fact that 
TRF estimates the length of telomeric sequences that also contain sub-telomeric re-
peats. These repeats can vary in length based on the last restriction site at a given 
chromosome arm, thus increasing the heterogeneity of TRFs and influencing the length 
of sub-telomeric repeats that prevents detection of the true length of telomere repeats 
[28]. Previous findings by Steinert et al. (2014) showed that sub-telomeres contain 2 - 
4kb of sequence that is resistant to enzymatic digestion [29]. TRF analysis provides an 
average telomere length for the sample (not even a mean length is obtained) and there-
fore may provide telomere lengths that are shorter than that obtained by other me-
thods. 
 
Table 1. Telomere length comparison of three methods: Telomere Restriction Fragment (TRF), 
quantitative PCR (data from [12]) and interphase-quantitative FISH (iQ-FISH). The average of 
untreated and DMSO-treated 21NT cell is compared to the average of the 5-aza-CdR-treated (all 
time points) and the 5-aza-CdR plus TSA-treated (all time points). 
Sample name 
Average Telomere  
Length-(kb) 
Average Telomere  
Length-uTFI 
TRF qPCR* iQ-FISH 
HMEC-p5 8.95 7.32 4.77 
21NT-DMSO and untreated 1.46 ± 0.19 2.55 ± 0.36 1.13 ± 0.45 
21NT-treated (5-aza-CdR) 2.52 ± 1.02† 4.22 ± 1.75‡ 2.96 ± 0.63* 
21NT-treated (5-aza-CdR + TSA) 2.30 ± 0.74†† 3.67 ± 1.20‡‡ 3.14 ± 0.41** 
†p = 0.0718 (90% CI), ††p = 0.0570 (90% CI), ‡p = 0.0026 (95% CI), ‡‡p = 0.0035 (95% CI), *p = 0.0232 (95% CI), **p 
= 0.0053 (95%CI). *Data from [12]. 
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In this article, we confirm telomere length increase in the breast cancer cell line 
21NT within 3 days of exposure to 5-aza-CdR. In some cases, the increase was as much 
as two fold. 5-aza-CdR is a global demethylatingagent, it will have the effect of altering 
the methylation pattern of many genes and pathways. It is known that 85% of cancers 
upregulate telomerase to maintain telomere lengths, the other 15% use the ALT path-
way to achieve the same goals [30]. In this paper, we have shown that both pre-spliced 
and fully spliced hTERT was upregulated 72 hours after 5-aza-CdR treatment (Figure 
6). The level of pre-spliced hTERT expression has been shown to correlate with telo-
merase activity [31]. Also [32] found that when human lymphoid and colon carcinoma 
cell lines were treated with 5-aza-CdR for 72 hours, a rapid increase in the telomeric 




Figure 4. Typical images from an iQ-FISH method. The cell nuclei were hybridized 
with telomeric PNA probe (Telo-PNA) tagged with green fluorescence signal 
(FITC) and DNA stained with DAPI (Blue). The total fluorescent intensities of each 
telomeric signal were converted digitally and the mean average were analyzed. Te-
lomere signals from primary HMECs (with known average telomere length of 9 - 12 
kb) are shown for comparison purposes. The scale bar = 10 µm. ×100 lens was used 
to capture DMSO control cells and ×63 lens was used for 5-aza-CdR treated and 
HMEC control cells. All backgrounds were taken into account when software were 
used to measure the telomeric signal using the iQ-FISH protocol. This is only a true 
representation of more than hundreds of images taken and the overall background 
is equal in all samples. 




(a)                                             (b) 
Figure 5. Scatter plot of individual telomere lengths measured using the described methods. De-
termination of telomere lengths usng qPCR technique has been reported in detail previously. The 
conversion of T/S ratio into telomere lengths in kilobases was done using a standard curve gener-
ated to measure absolute telomere lengths of a sample with known telomere lengths as described 
previously. (a) Serial dilution of the telomere standard starting with 1,018,400 kb to 10,184 kb was 
used to measure the content of telomeric sequences per sample in kb. (b) Single gene copy gene 
(36B4) was used as control for every reaction and to determine the genome copies of each sample. 
The values generated from the qPCR reaction and the standard curves (Figure 5(b)) were used to 
calculate the total telomere length in kb per human diploid genome. The telomere kb length per 
reaction value was then divided by diploid genome copy number to give a total telomeric length 
in kb per human diploid genome. 
 
 
Figure 6. Gene expression analysis of pre- and fully-spliced 
hTERT mRNA. 21NT cells were treated with 5-aza-CdR or 
DMSO for 72 hours before RNA extraction and analysis. 
Relative qPCR was then performed for both pre-spliced 
and spliced hTERT using primers from [31]. 
 
crease telomere lengths. Therefore it is possible that a combination of both hTERT 
(hence telomerase) up-regulation and an increase in T-SCE may have contributed to  
the rapid increase in telomere length we observed. We have previously shown [12] that 
5-aza-CdR upregulates several members of the Shelterin complex simultaneously. This 
may also play a role in the rapid increase in telomere length observed as POT1 and 
TPP1 have been shown to be involved in telomerase regulation [33]. 
Our previous study has shown similar telomere length elongation in two other breast 
cancer cell lines, BT474 and MCF7 upon treatment with 5-aza-CdR and TSA assessed 
with q-PCR [12]. Therefore, the current observation reported here is consistent with 
our previous study, marking the epigenetic regulation of telomere length maintenance 
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an important area to be considered in clinical therapeutic approaches. 
Increase in telomere length may influence the clinical outcome of patients treated 
with drugs such as 5-aza-CdR and TSA. For instance, prostate and breast cancer cell 
lines that have elongated telomeres through hTERT overexpression show signs of dif-
ferentiation in vitro [34] compared to their parental cell type. Whereas, hepatocellular 
carcinoma cells (HCC) with long telomeres tend to develop greater invasive ability 
compared to similar HCC with short telomeres [35]. Therefore, the mechanism of te-
lomere length elongation through epigenetic regulating drug needs to be further inves-
tigated. 
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